HDL and apabetalone
posted on
Apr 23, 2022 11:42AM
This is why I would like RVX management to get on with BoM2 and get apabetalone approved for MACE type issues.
Like millions of people I’m trying to manage my PAD (peripheral artery disease). I walk 3 km each day (used to jog 6 km/day), do an exercise routine, have become a vegetarian (based on the book Eat to Live) and I’m well on my way to reducing my weight to 155 lbs. A brief online search revealed the following;
So I went back to look at the SUSTAIN trial results. Great news.
RVX Sustain - Fierce Biotech Aug 28 2012
Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period.
Resverlogix Corp. CA:RVX +11.46% today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C (p=0.001), the primary endpoint of the SUSTAIN trial, a phase 2b clinical study. SUSTAIN also successfully met secondary endpoints, showed increases in levels of Apo-AI (p=0.002) and large HDL particles (p=0.02), both believed to be important factors in enhancing reverse cholesterol transport activity. The SUSTAIN trial also showed that increases in alanine aminotransferase (ALT) reported in previous trials were infrequent and transient with no new increases observed beyond week 12 of the 24-week trial.
I would be taking apabetalone right now if I could get my hands on it.
Anyway, those are pretty significant HDL statistics. Too bad that the subsequent study of plaque regression was statistically underpowered.
Time to change management and get on with BoM2.
GLTA
Toinv